Lifeward Ltd. 8K

Lifeward Ltd. announced Q2 2026 results with higher revenue and liquidity from new financing alongside board resignations and an upcoming CFO transition.

On August 14, 2026, Lifeward Ltd. reported its financial results for the quarter ended June 30, 2026, highlighting a 16% year-over-year revenue increase to $6.6 million driven by growth in ReWalk and AlterG product sales, a strengthened liquidity position with a pro forma cash balance of approximately $11 million following a July 6, 2026 strategic financing of up to $11.2 million, and ongoing investment in its restorative healthcare and oral insulin (ORMD-0801) programs, while also disclosing governance and leadership changes including the resignation of Chairman Bob Marshall and directors Mike Swinford and William Sigsbee effective August 13, 2026 and the planned departure of Chief Financial Officer Almog Adar effective September 30, 2026.

Filing Facts

CIK

1607962

Ticker

-

Form

8K

Source Type

sec

Accession

0001178913-26-004140

Alert Tier

7